clinical trial · NCT07015242
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·phase2·recruiting·n = 65
LymphomaRituximabMethotrexateProcarbazineTemozolomideLiso-celFludarabineCyclophosphamideCalcium folinate
brief summary
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
started
Nov 6, 2025
primary completion
Jan 9, 2028
completion
Dec 10, 2028
last updated
Jun 10, 2026
official title
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol